Related Experiment Video

Updated: Jul 19, 2026

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

Gene therapy for cystic fibrosis lung disease: current status and future perspectives

Josef Rosenecker1, Stephanie Huth, Carsten Rudolph

  • 1Department of Pediatrics, Ludwig-Maximilians-Universität München, Lindwurmstr 4, D-80337 München, Germany. joseph.rosenecker@med.uni-muenchen.de

Current Opinion in Molecular Therapeutics
|November 3, 2006
PubMed

Insights

Gene therapy for cystic fibrosis (CF) aims to deliver the CFTR gene to the lungs. Current non-viral methods show promise but require improved efficiency and duration for effective CF treatment.

Area of Science:

  • * Genetics and Molecular Biology
  • * Pulmonary Medicine
  • * Biotechnology

Background:

  • * Cystic Fibrosis (CF) is a severe autosomal recessive genetic disorder affecting over 70,000 people globally.
  • * Current CF therapies have limitations, with most patients not surviving past their early 30s.
  • * Gene therapy targeting the cystic fibrosis transmembrane regulator (CFTR) gene offers a potential curative approach.

Purpose of the Study:

  • * To review current gene therapy vectors for CF lung delivery.
  • * To discuss novel strategies for enhancing gene transfer efficiency and selectivity.
  • * To address the need for improved and prolonged transgene expression in the respiratory epithelium.

Main Methods:

  • * Review of existing clinical studies on viral and non-viral gene therapy for CF.
  • * Analysis of non-viral vectors such as cationic liposome/plasmid DNA complexes and compacted DNA nanoparticles.
  • * Discussion of strategies to overcome challenges in gene transfer and immune responses.

Main Results:

  • * Proof-of-principle for chloride channel correction in CF patients using gene therapy has been demonstrated.
  • * Non-viral vectors are promising but have shown insufficient CFTR expression levels and duration in Phase I trials.
  • * Viral vectors can elicit host-antigen-specific immune responses, limiting their therapeutic potential.

Conclusions:

  • * Significant advancements have been made in CF gene therapy, particularly with non-viral vectors.
  • * Further research is crucial to enhance the efficiency and duration of CFTR gene expression for effective CF treatment.
  • * Novel strategies are needed to optimize gene delivery to the lungs for long-term therapeutic benefit.

More Related Videos

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice08:55

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Published on: July 4, 2018

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...